[Skip to Navigation]
Views 3,718
Citations 0
Editor's Note
June 28, 2021

Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas: The Price of Prevention

Author Affiliations
  • 1Department of Medicine, University of California, San Francisco
  • 2Editorial Fellow, JAMA Internal Medicine
  • 3Division of Research, Kaiser Permanente Northern California, Oakland
  • 4Associate Editor, JAMA Internal Medicine
JAMA Intern Med. 2021;181(8):1054. doi:10.1001/jamainternmed.2021.2487

The number of different medications available to treat patients with type 2 diabetes has increased dramatically over the past 2 decades. While metformin remains the mainstay of initial treatment, there is ongoing debate regarding the optimal choice when adding a second oral agent. In this issue of JAMA Internal Medicine, Xie et al1 examine the comparative effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors vs sulfonylureas on all-cause mortality among metformin users. This high-dimensional propensity score–matched cohort study observed patients enrolled in the Veterans Affairs health system who were receiving metformin and were prescribed either an SGLT2 inhibitor or sulfonylurea as a second medication. During the approximately 2 years of mean follow-up, SGLT2 inhibitor use was associated with a reduced risk of all-cause mortality compared with sulfonylureas, regardless of age, cardiovascular disease, or estimated glomerular filtration rate status (hazard ratio [HR], 0.81; 95% CI, 0.75-0.87).1 There was also a reduced risk of death with the combination of SGLT2 inhibitor and metformin compared with SGLT2 inhibitor use alone (HR, 0.70; 95% CI, 0.50-0.97).1 These findings reinforce the current American Diabetes Association guidelines,2 which recommend metformin as initial therapy followed by any one of a dipeptidyl peptidase-4 inhibitor, glucagonlike peptide-1 receptor agonist, thiazolidinedione, or SGLT2 inhibitor class medicine if a patient’s hemoglobin A1c level remains elevated.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words